A Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of INT131 Besylate Compared to Pioglitazone in Subjects With Type 2 Diabetes.
Latest Information Update: 20 Nov 2015
At a glance
- Drugs Ibrigampar (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors InteKrin Therapeutics
- 18 Jun 2010 Six-month data will be presented at the American Diabetes Association annual meeting in June 2010, according to an InteKrin Therapeutics media release.
- 08 Oct 2009 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.
- 02 Oct 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).